Company Filing History:
Years Active: 2019-2025
Title: Innovations of Donghoon Choi
Introduction
Donghoon Choi is a prominent inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for viral infections. With a total of eight patents to his name, Choi's work is recognized for its potential impact on public health.
Latest Patents
One of Choi's latest patents is focused on a pharmaceutical composition that utilizes an immunoglobulin Fc-fused interleukin-7 fusion protein. This invention aims to prevent or treat diseases caused by influenza virus A. The fusion protein, which combines the immunoglobulin Fc region with IL-7, offers protection against infections and can effectively treat diseases associated with the virus. Another notable patent involves the formulation of a modified interleukin-7 fusion protein. This pharmaceutical formulation includes a modified IL-7 protein, a basal buffer, a sugar, and a surfactant. It is designed to prevent aggregate formation and protect proteins under stress conditions, making it a valuable option for patient treatment.
Career Highlights
Donghoon Choi is currently associated with Genexine, Inc., a company known for its innovative approaches in biotechnology. His work at Genexine has allowed him to focus on developing advanced therapeutic solutions that address critical health challenges.
Collaborations
Choi collaborates with talented individuals such as Se Hwan Yang and Hye Seong Lim. Their combined expertise contributes to the success of their projects and enhances the innovative capacity of their team.
Conclusion
Donghoon Choi's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for advancements in the treatment of viral infections, showcasing the importance of innovation in healthcare.